{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Estrogen+Receptor+Positive+Tumor&page=2", "query": { "condition": "Estrogen Receptor Positive Tumor", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Estrogen+Receptor+Positive+Tumor&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T10:38:43.367Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01697293", "title": "PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Adenocarcinoma", "Estrogen Receptor Positive", "HER2/Neu Negative", "Recurrent Breast Carcinoma", "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Triciribine Phosphate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Prescient Therapeutics, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2012-01", "completion_date": "2020-06", "has_results": false, "last_update_posted_date": "2020-09-24", "last_synced_at": "2026-06-10T10:38:43.367Z", "location_count": 2, "location_summary": "Tampa, Florida • The Bronx, New York", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01697293" }, { "nct_id": "NCT00097344", "title": "The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms", "Neoplasms, Hormone-Dependent" ], "interventions": [ { "name": "Atamestane", "type": "DRUG" }, { "name": "Toremifene", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Aromatase inhibition", "type": "DRUG" }, { "name": "Estrogen receptor blocker", "type": "DRUG" }, { "name": "Hormone therapy", "type": "PROCEDURE" }, { "name": "Endocrine therapy", "type": "PROCEDURE" }, { "name": "Antiestrogen therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Intarcia Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 842, "start_date": "2004-12", "completion_date": "2006-08", "has_results": false, "last_update_posted_date": "2007-08-23", "last_synced_at": "2026-06-10T10:38:43.367Z", "location_count": 49, "location_summary": "Mobile, Alabama • Tuscon, Arizona • Hot Springs, Arkansas + 46 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tuscon", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Greenbrae", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00097344" }, { "nct_id": "NCT07100106", "title": "A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "GDC-4198", "type": "DRUG" }, { "name": "Giredestrant", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 285, "start_date": "2025-10-07", "completion_date": "2028-08-31", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-06-10T10:38:43.367Z", "location_count": 16, "location_summary": "Duarte, California • Irvine, California • La Jolla, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07100106" }, { "nct_id": "NCT04443348", "title": "Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer", "Hormone Receptor Positive (HR+), HER2-negative Breast Cancer", "Biopsy-proven, Positive Lymph Node(s)" ], "interventions": [ { "name": "Radiation Therapy Boost", "type": "RADIATION" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Laura M. Spring, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2020-12-16", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-06-10T10:38:43.367Z", "location_count": 10, "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 6 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04443348" }, { "nct_id": "NCT01515800", "title": "S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Text message reminder", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 724, "start_date": "2012-05", "completion_date": "2018-02", "has_results": false, "last_update_posted_date": "2018-03-08", "last_synced_at": "2026-06-10T10:38:43.367Z", "location_count": 204, "location_summary": "Anchorage, Alaska • Fort Smith, Arkansas • Little Rock, Arkansas + 144 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Antioch", "state": "California" }, { "city": "Fremont", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01515800" }, { "nct_id": "NCT00049062", "title": "Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "anastrozole", "type": "DRUG" }, { "name": "gefitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "2002-09", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2013-02-21", "last_synced_at": "2026-06-10T10:38:43.367Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00049062" }, { "nct_id": "NCT06538389", "title": "High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage 0 Breast Cancer AJCC v8", "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Breast Adenocarcinoma", "Breast Ductal Carcinoma In Situ", "Estrogen Receptor-Positive Breast Carcinoma", "Progesterone Receptor-Positive Breast Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "BRC-001", "type": "DRUG" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 36, "start_date": "2024-08-26", "completion_date": "2027-01-24", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-06-10T10:38:43.367Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06538389" }, { "nct_id": "NCT03709082", "title": "Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "Breast Cancer Metastatic" ], "interventions": [ { "name": "Palbociclib 75mg", "type": "DRUG" }, { "name": "Letrozole 2.5mg", "type": "DRUG" }, { "name": "T-DM1", "type": "DRUG" }, { "name": "Palbociclib 100mg", "type": "DRUG" }, { "name": "Palbociclib 125mg", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 3, "start_date": "2018-10-15", "completion_date": "2021-02-03", "has_results": false, "last_update_posted_date": "2024-03-05", "last_synced_at": "2026-06-10T10:38:43.367Z", "location_count": 5, "location_summary": "Kansas City, Kansas • Overland Park, Kansas • Kansas City, Missouri + 1 more", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Lee's Summit", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03709082" }, { "nct_id": "NCT04132817", "title": "A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2020-09-22", "completion_date": "2022-08-15", "has_results": false, "last_update_posted_date": "2022-12-02", "last_synced_at": "2026-06-10T10:38:43.367Z", "location_count": 8, "location_summary": "Los Angeles, California • Sacramento, California • Aurora, Colorado + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04132817" }, { "nct_id": "NCT01856036", "title": "Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Cryoablation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Saint John's Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2013-04", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2017-02-07", "last_synced_at": "2026-06-10T10:38:43.367Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01856036" } ] }